Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | GNG2 | P59768 | 1/20 | 0.31 |
| ▸ | GNB1 | P62873 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24960169 | 0.80 | MAPT (0.45) | MAPTNLRP3GNG2GNB1LMNA | |
| SCHEMBL20713668 | 0.80 | MAPT (0.47) | MAPK1MAPTNLRP3GNG2GNB1 | |
| SCHEMBL22280260 | 0.77 | MEN1 (0.41) | MAPK1MEN1KMT2ANPSR1HSD17B1 | |
| SCHEMBL11801437 | 0.77 | HSD17B1 (0.38) | HSD17B1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL24960267 | 0.77 | MAPT (0.38) | MAPK1MEN1KMT2ANPSR1HSD17B1 | |
| SCHEMBL31474402 | 0.76 | MAPT (0.43) | MAPK1MEN1KMT2AMAPTNLRP3 | |
| SCHEMBL22011681 | 0.74 | MEN1 (0.41) | MAPK1MEN1KMT2ANPSR1HSD17B1 | |
| SCHEMBL18393609 | 0.74 | MAPK1 (0.41) | MAPK1MEN1KMT2ANPSR1HSD17B1 | |
| SCHEMBL18007624 | 0.74 | MEN1 (0.41) | MAPK1MEN1KMT2ANPSR1HSD17B1 | |
| SCHEMBL24294871 | 0.73 | MEN1 (0.38) | MAPK1MEN1KMT2ANPSR1HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200087270-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087270-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MAPK1 1647/4885MEN1 3390/4885KMT2A 4441/4885 |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MAPK1 1499/4885MEN1 3418/4885KMT2A 4433/4885 |
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | MAPK1 1647/4885MEN1 3390/4885KMT2A 4441/4885 |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MAPK1 1904/4885MEN1 2868/4885KMT2A 2653/4885 |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MAPK1 1647/4885MEN1 3390/4885KMT2A 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.